A Single-center, Open-label, Single-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Nalmefene 10 mg Tablets in Healthy Japanese Male Subjects

Status:
Completed

Trial end date:
2016-03-01

Target enrollment:

Participant gender:

The safety, tolerability, and pharmacokinetics of nalmefene at a single oral dose of 10 mg in healthy Japanese male subjects will be evaluated.

Phase 1

Otsuka Pharmaceutical Co., Ltd.

H. Lundbeck A/S

Nalmefene
Naltrexone